TWiV 1044: Clinical update with Dr. Daniel Griffin
Episode description
In his weekly clinical update, Dr. Griffin discusses the immunogenicity and reactogenicity of coadministration of COVID-19 and Influenza vaccines, interim effectiveness estimates of 2023 southern hemisphere influenza vaccines in preventing Influenza-associated hospitalizations, genome-wide association study of susceptibility to RSV hospitalization in young children <5 years of age, performance of rapid antigen tests to detect symptomatic and asymptomatic SARS-CoV-2 infection, safety and immunogenicity of XBB.1.5-containing mRNA vaccines, optimal duration of systemic corticosteroids in COVID-19 treatment, timing and predictors of loss of infectivity among healthcare workers with mild primary and recurrent COVID-19, and effects of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Immunogenicity and reactogenicity of coadministration of COVID-19 and Influenza vaccines (JAMA)
- Effectiveness estimates of Influenza vaccines in preventing associated hospitalizations (CDC)
- Genome-wide association study of susceptibility to RSV hospitalization in children (JID)
- Performance of rapid antigen tests to detect SARS-CoV-2 infection (AIN)
- Safety and immunogenicity of XBB.1.5-containing mRNA vaccines (medRxiv)
- C.D.C. director explains why you should get the latest Covid booster (Nytimes)
- Optimal duration of systemic corticosteroids in COVID-19 treatment (OFID)
- Timing and predictors of loss of infectivity among healthcare workers with COVID-19 (CID)
- Effect of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection (JPR)
- Contribute to our Floating Doctors fundraiser at PWB
- Letters read on TWiV 1044
- Dr. Griffin’s COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]